B-cell acute lymphoblastic leukemia is the most common form of childhood cancer. In this type of cancer, which affects blood ...

Bristol Myers’ BMY CAR T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) posted strong growth in 2025. Breyanzi is ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

By using CRISPR/Cas9 to engineer cells from healthy donors, AVC-203 is designed to circumvent graft-versus-host disease and host-mediated rejection.

Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Researchers are advancing CAR T-cell therapy for solid tumors using armored cells that deliver IL-36γ. Expanded manufacturing ...

Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.

Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia ...

Researchers say study lays groundwork for tailored sex-specific strategies to monitor and improve immune health across lifespan.

IGHV mutational status has long been used by clinicians to predict how CLL will behave and when treatment may be needed. 2 ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...